Diisopropylethylamine → 1-[(6-Bromopyridin-2-yl)methyl]-4-methyl-1,4-azaphosphinane 4-oxide

HRID 386036Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 386036
[Br:1][C:2]1[CH:7]=[CH:6][CH:5]=[C:4]([CH2:8]Br)[N:3]=1.Cl.[CH3:11][P:12]1(=[O:18])[CH2:17][CH2:16][NH:15][CH2:14][CH2:13]1.CCN(C(C)C)C(C)C>CN(C=O)C>[Br:1][C:2]1[N:3]=[C:4]([CH2:8][N:15]2[CH2:16][CH2:17][P:12](=[O:18])([CH3:11])[CH2:13][CH2:14]2)[CH:5]=[CH:6][CH:7]=1

Komponenten

5

Edukt 3

HCID 81531DiisopropylethylamineHCID 129547962-Bromo-6-(bromomethyl)pyridineHCID 668330534-Methyl-1,4lambda5-azaphosphinan-4-one hydrochloride

Produkt 1

HCID 595256551-[(6-Bromopyridin-2-yl)methyl]-4-methyl-1,4-azaphosphinane 4-oxide

Reagenzien, Katalysatoren, Lösungsmittel 1

HCID 6228DimethylformamideLösungsmittel

Versuchsvorschrift

2-Bromo-6-(bromomethyl)pyridine (Example 190, Step 1) (500 mg, 1.99 mmol), 4-methyl-1,4-azaphosphinane 4-oxide hydrochloride (406 mg, 2.39 mmol, prepared according to the method described in WO 2008/010985), and DIEA (522 μL, 2.99 mmol) were combined in DMF (5.0 mL) and stirred at room temperature overnight. The solvent was then evaporated in vacuo and the crude residue was purified by reverse phase HPLC (MeCN/water w/0.025% TFA) to afford the title compound as a colorless foam.

Aufarbeitung

  1. customThe solvent was then evaporated in vacuo
  2. customthe crude residue was purified by reverse phase HPLC (MeCN/water w/0.025% TFA)

Quellen und Nachweise

ORD-Eintrag
ord-49627ba2896446df9858ad963bc822cb
Quelldatensatz
uspto-grants-2013_02
Patentnummer
US08367706B2

Notizen zur Reaktion

Wird geladen…